@article{2841aff0593a4902a9da2ad5d5781140,
title = "Improved methods for RNAseq-based alternative splicing analysis",
abstract = "The robust detection of disease-associated splice events from RNAseq data is challenging due to the potential confounding effect of gene expression levels and the often limited number of patients with relevant RNAseq data. Here we present a novel statistical approach to splicing outlier detection and differential splicing analysis. Our approach tests for differences in the percentages of sequence reads representing local splice events. We describe a software package called Bisbee which can predict the protein-level effect of splice alterations, a key feature lacking in many other splicing analysis resources. We leverage Bisbee{\textquoteright}s prediction of protein level effects as a benchmark of its capabilities using matched sets of RNAseq and mass spectrometry data from normal tissues. Bisbee exhibits improved sensitivity and specificity over existing approaches and can be used to identify tissue-specific splice variants whose protein-level expression can be confirmed by mass spectrometry. We also applied Bisbee to assess evidence for a pathogenic splicing variant contributing to a rare disease and to identify tumor-specific splice isoforms associated with an oncogenic mutation. Bisbee was able to rediscover previously validated results in both of these cases and also identify common tumor-associated splice isoforms replicated in two independent melanoma datasets.",
author = "{C4RCD Research Group} and Halperin, {Rebecca F.} and Apurva Hegde and Lang, {Jessica D.} and Raupach, {Elizabeth A.} and Vinodh Narayanan and Matt Huentelman and Newell Belnap and Aziz, {Anne Marie} and Keri Ramsey and Christophe Legendre and Liang, {Winnie S.} and LoRusso, {Patricia M.} and Aleksandar Sekulic and Sosman, {Jeffrey A.} and Trent, {Jeffrey M.} and Sampathkumar Rangasamy and Patrick Pirrotte and Schork, {Nicholas J.}",
note = "Funding Information: The development and evaluation of Bisbee was funded by the Sylvia Chase Early Career award to RFH as well as donations from Dell, Inc. AH, EAR, JL and PP are funded in part by R01 CA195670. NJS is funded in part by NIH grants UH2 AG064706, U19 AG023122, U24 AG051129, U24 AG051129-04S1; NSF grant (FAIN number) 2031819; and the Ivy and Ottesen Foundations. RS and the C4RCD team is supported by private donations to the TGen Foundation and Center for Rare Childhood Disorders (C4RCD). The melanoma patient study was funded by a Stand Up To Cancer (SU2C) – Melanoma Research Alliance Melanoma Dream Team Translational Cancer Research Grant (#SU2C-AACR-DT0612) and the Gateway for Cancer Research Foundation (#G-12–500). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (AACR). Research reported in this publication included work performed in the Mass Spectrometry & Proteomics Core Facility supported by the National Cancer Institute of the National Institutes of Health under grant number P30CA033572. This work was also supported by the Ovarian Cancer Research Alliance [Ann and Sol Schreiber Mentored Investigator Award 650001] to EAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
month = dec,
doi = "10.1038/s41598-021-89938-2",
language = "English (US)",
volume = "11",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",
}